DBV Technologies SA · EURONEXT:DBV
DBV Technologies SA — Investor Presentation (September 2021)
35 slides from DBV Technologies SA's investor presentation, September 2021
Slide 1: September 2021
September 2021 2021-MLR-070
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or success of DBV’s clinical trials; its ability to successfully gain regulatory approvals and commercialize products; its ability to successfully advance its
Slide 3: DBV is a global, clinical-stage biopharmaceutical company
DBV IS A GLOBAL, CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY We are dedicated to improving the lives of patients with food allergies and other immunological diseases Our science-driven leadership team has deep regulatory and commercial experience We have a dedicated team of ~100 professionals, with loc
Slide 4: EPIT aims to re-educate the immune system by inducing specific regulatory T cells
EPICUTANEOUS IMMUNOTHERAPY (EPIT™) AIMS TO RE-EDUCATE THE IMMUNE SYSTEM BY INDUCING SPECIFIC REGULATORY T CELLS1-6 Regulatory T Cells act on the immune system to alter allergic response EPIT delivers allergen • Decrease in allergen-specific IgE to intact skin Antigen Presenting Cells capture allerge
Slide 5: The Viaskin patch uses minimal amounts of antigen to induce an immune response
THE VIASKIN™ PATCH, OUR NOVEL APPROACH TO EPIT, USES MINIMAL AMOUNTS OF ANTIGEN TO INDUCE AN IMMUNE RESPONSE1-4 The condensation chamber enables natural epidermal water loss to solubilize dry antigen deposited on the patch using an innovative electrospray technology Condensation chamber Solubilized
Slide 6: Viaskin has multiple potential applications in food allergies and other immunological conditions
VIASKIN™ HAS MULTIPLE POTENTIAL APPLICATIONS IN FOOD ALLERGIES AND IN OTHER IMMUNOLOGICAL CONDITIONS Epicutaneous immunotherapy and Viaskin are under clinical investigation and have not been approved for marketing by any health or regulatory authority. 6
Slide 7: Multiple unmet needs in the management of peanut allergy
THERE ARE MULTIPLE UNMET NEEDS CONCERNING THE MANAGEMENT OF PEANUT ALLERGY More Children Are Living with Peanut Allergy Than Ever Before • 860K children ages 4–11 have peanut allergy in the US,1,2 ~480K in EU2 • ~80% will not outgrow their allergy3 For Many Families, Avoidance Is Not Enough • Accide
Slide 8: Allergists, families, and children want additional protection from accidental peanut exposure
ALLERGISTS, FAMILIES, AND CHILDREN WANT ADDITIONAL PROTECTION FROM ALLERGIC REACTIONS DUE TO ACCIDENTAL PEANUT EXPOSURE Caregivers and physicians are seeking a treatment that1,2: 1. Reduces the likelihood of an allergic reaction in case of accidental exposure 2. Has a low risk of a serious reaction
Slide 9: Occurrence of reactions is determined by eliciting dose and exposure dose
OCCURRENCE OF REACTIONS IS DETERMINED BY THE RELATIONSHIP BETWEEN ELICITING DOSE AND EXPOSURE DOSE Eliciting Dose Exposure Dose Reaction Prediction The amount of allergen that induces The amount of allergen accidentally An allergic reaction is predicted to occur when a unmistakable allergic symptoms
Slide 10: Modeling data suggest increasing eliciting dose decreases risk of allergic reaction
MODELING* DATA SUGGEST INCREASING A PATIENT’S ELICITING DOSE DECREASES THE RISK OF AN ALLERGIC REACTION1 Decrease in Reaction Risk Following Allergen Immunotherapy ED after allergen immunotherapy 1,000 mg ED after allergen 300 mg 300 mg immunotherapy ED before allergen immunotherapy 100 mg 30 mg ED
Slide 11: Viaskin Peanut clinical program
VIASKIN™ PEANUT CLINICAL PROGRAM: COMMITTED TO GENERATING LONG-TERM DATA TO INFORM REAL-LIFE USE1 Phase 1 Phase 2b Phase 3 PEP01.09 VIPES 6-50 years of age 6-55 years of age 4-11 years of age 4-11 years of age 1-3 years of age 100 patients 221 patients 356 patients 393 patients 414 patients 2-week t
Slide 12: Efficacy data of Viaskin Peanut in children ages 4–11 years
EFFICACY DATA OF VIASKIN™ PEANUT IN CHILDREN AGES 4–11 YEARS Pivotal Phase 3 Study (PEPITES)1 Open-label Follow-on Study (PEOPLE)2 After 12 months, a 51.8% of subjects reached an ED of ≥1,000 mg at significantly larger Month 36, compared to 40.4% at Month 12 percentage of participants responded to V
Slide 13: Viaskin Peanut safety information from clinical trials to date
VIASKIN™ PEANUT SAFETY INFORMATION FROM CLINICAL TRIALS TO DATE1,2 Most Common AEs Treatment-related Anaphylaxis* and In PEPITES (Months 0–12) and PEOPLE (Months 12–36), Epinephrine Use the most commonly reported treatment-related AEs 8 (3.4%) Viaskin Peanut participants experienced were local a
Slide 14: Viaskin Peanut may offer a convenient, easy-to-use treatment
IF APPROVED, VIASKIN PEANUT MAY OFFER A CONVENIENT, EASY-TO-USE TREATMENT FOR PATIENTS AND THEIR FAMILIES Viaskin Peanut is designed to have the following features: Applied at home, once a day No treatment escalation, minimizing number of extra doctor's appointments No activity limitations N
Slide 15: Pursuing potential approval of Viaskin Peanut in children 4–11 in the US
VIASKIN PEANUT WE ARE PURSUING POTENTIAL APPROVAL OF VIASKIN™ US PEANUT IN CHILDREN AGES 4–11 IN THE UNITED STATES Complete Response Letter (CRL) received in August 2020. FDA identified the following concerns1: – Impact of patch-site adhesion on efficacy – Need for patch modifications and supplement
Slide 16: Significant progress in developing modified patches and mVP clinical study efforts
VIASKIN PEANUT SIGNIFICANT PROGRESS MADE IN DEVELOPING MODIFIED US PATCHES AND MVP CLINICAL STUDY EFFORTS Patch Modification mVP Clinical Development Plan Identify potential modifications CHAMP: Modified patch study (5 mVPs, 1 cVP) in healthy adult volunteers Produce modified patch prototypes
Slide 17: EMA review of Viaskin Peanut MAA proceeding according to standard timeline
VIASKIN PEANUT EMA REVIEW OF VIASKIN™ PEANUT MAA PROCEEDING EU ACCORDING TO STANDARD EVALUATION TIMELINE1 Primary Clock Secondary Clock Final CHMP Pre-submission Validation Evaluation Stop* Evaluation Stop* Evaluation Opinion Day 0 Day Day Day Day Day Day Day 1 120 121 180 181 210 277 4Q 2020 1Q 202
Slide 18: Continued financial diligence maintains operating latitude
CONTINUED FINANCIAL DILIGENCE MAINTAINS OPERATING LATITUDE TO PROGRESS VIASKIN™ PEANUT Average Monthly Cash Used in Operations Cash balance of $125.5 million at end of 2Q $, millions 2021 20 Cash and cash equivalents to support business operations until 2H 2022 15 Global cost reduction program
Slide 19: Upcoming catalysts
UPCOMING CATALYSTS 2H EMA Review Continues 2021 EQUAL, STAMP Protocol 2H Finalization 2021 October 3Q 2021 Financial Results 2021 Epicutaneous immunotherapy and Viaskin are under clinical investigation and have not been approved for marketing by any health or regulatory authority. 19
Slide 20: DBV Contacts
DBV CONTACTS Investor Relations Partnering and Licensing Anne Pollak general.inquiries@dbv-technologies.com +1 857-529-2363 anne.pollak@dbv-technologies.com Clinical Trial Participation clinicaltrials@dbv-technologies.com Public Relations and Media Angela Marcucci Medical Information +1 646-842-2393
Slide 21: Appendix: Clinical trial data for Viaskin Peanut
APPENDIX: CLINICAL TRIAL DATA FOR VIASKIN PEANUT
Slide 22: Key publications
KEY PUBLICATIONS Dioszeghy V, Mondoulet L, Dhelft V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol. 2011;186(10):5629-5637. Mondoulet L, Dioszeghy V, Puteaux
Slide 23: PEPITES and its 5-year open-label extension PEOPLE
PEPITES AND ITS 5-YEAR, OPEN-LABEL EXTENSION, PEOPLE, IS THE LONGEST-TERM PEANUT IMMUNOTHERAPY TRIAL PEPITES (Viaskin™ Peanut 250 µg vs Placebo)1 PEOPLE (Viaskin Peanut 250 µg)2 M12 M24 M36 M38 M48 M60 Rollover to VP 250 µg 356 patients Placebo (n=118) n=107 n=100 91 83 • 4–11 years old • Confirmed
Slide 24: Viaskin Peanut treatment effect after 12 months
VIASKIN™ PEANUT TREATMENT EFFECT AFTER 12 MONTHS1 Change in Eliciting Dose Response Rate After 12 Months* After 12 Months† 40% P<0.001 100% 28.0% ED Increase 35.3% 80% 30% ED Stable Percent of Subjects Δ= 21.7% 62.6% ED Decrease (95% CI: 12.4, 29.8) 60% 20% 38.1% 40% 10% 13.6% 20% 30.7% 33.9% 0% 0%
Slide 25: Change in cumulative reactive dose and eliciting dose with long-term treatment
CHANGE IN CUMULATIVE REACTIVE DOSE (CRD) AND ELICITING DOSE WITH LONG-TERM VIASKIN™ PEANUT TREATMENT1 Cumulative Reactive Dose (mg) Mean, Median (-) PEOPLE Per Protocol (N=141) 3,000 2,500 75.9% of subjects demonstrated an increase in ED from baseline to Month 36 2,000 1768.8 1,500 51.8% of subjects
Slide 26: Most commonly reported treatment-related adverse events
MOST COMMONLY REPORTED TREATMENT-RELATED ADVERSE EVENTS PEPITES: Treatment-related TEAEs (occurring in ≥5% of subjects in 12 months)1 100% Placebo, n=118 Viaskin™ Peanut 250 µg, n=238 No treatment-related 80% gastrointestinal AEs observed % Subjects 59.7% 57.6% 60% 40% 34.7% 27.1% 20% 8.5% 5.5% 5.0%
Slide 27: Change in frequency and severity of local administration site reactions
CHANGE IN FREQUENCY AND SEVERITY OF LOCAL ADMINISTRATION SITE REACTIONS AFTER MONTH 1 Local Administration Site Reactions in the Viaskin™ Peanut 250 µg Group Over Time1* Grade 4 Grade 3 Grade 2 Grade 1† 100% In the extension study period between 83.4% 82.3% 12 and 36 months2: 76.9% 80% 72.6% The m
Slide 28: Rates of treatment-related anaphylaxis and epinephrine use
RATES OF TREATMENT-RELATED ANAPHYLAXIS* AND EPINEPHRINE USE1,2 8 (3.4%) Viaskin™ Peanut participants experienced 10 Treatment-related TEAEs leading to events of treatment-related anaphylaxis* in 12 epinephrine use from M0–M12 months of treatment 10% – All were graded as mild or moderate without ev
Slide 29: Treatment adherence and discontinuation rates
TREATMENT ADHERENCE AND DISCONTINUATION RATES WITH VIASKIN™ PEANUT OBSERVED OVER 12, 36 MONTHS 98.5% treatment compliance at 12 months, comparable between Viaskin Peanut and placebo groups A mean compliance of 98% was observed over 3 years of treatment 89.9% of all subjects completed the 12-mo
Slide 30: Clinical relevance of increasing a patient's eliciting dose
CLINICAL RELEVANCE OF INCREASING A PATIENT’S ELICITING DOSE THROUGH ALLERGEN IMMUNOTHERAPY Decrease in risk of reaction as a function of increasing eliciting dose1 (example: ice cream) A single peanut kernel contains ~250 to 300 mg of peanut protein2 Post-immunotherapy ED (mg peanut protein) The
Slide 31: Predicted risk reduction of allergic reactions from peanut-contaminated foods
PREDICTED RISK REDUCTION OF ALLERGIC REACTIONS CAUSED BY PEANUT-CONTAMINATED FOODS WITH VIASKIN™ PEANUT TREATMENT Modeling based on clinical trial data Risk reduction per Viaskin Peanut with Viaskin Peanut predicts: eating occasion1 250 µg Placebo 73%–78% reduction in the risk of an Cookies -77.7%
Slide 32: Predicted risk reduction for allergic reactions after 12 months of treatment
PREDICTED RISK REDUCTION FOR ALLERGIC REACTIONS AFTER 12 MONTHS OF VIASKIN™ PEANUT TREATMENT1 Number needed to treat with Viaskin Peanut 250 µg 5.5 children for 12 months to prevent 1 allergic reaction Number needed to treat with Viaskin Peanut 250 µg for 9.4 children 12 months to prevent 1 moderate
Slide 33: Change in children's quality of life observed at 2 years
CHANGE IN CHILDREN’S QUALITY OF LIFE WITH VIASKIN™ PEANUT OBSERVED AT 2 YEARS1 LS Mean Change from Baseline to Year 2 in FAQLQ Total Scores* Viaskin Peanut 250 µg during year 1 Placebo during year 1 FAQLQ Parent form (proxy)† FAQLQ Child form 0.4 N=89 0.2 0.08 0 -0.2 -0.4 -0.26 N=175 -0.39 -0.6 N=42
Slide 34: Change in severity of allergic reactions with Viaskin Peanut treatment
CHANGE IN SEVERITY OF ALLERGIC REACTIONS WITH VIASKIN™ PEANUT TREATMENT1 Less severe symptoms with Viaskin Peanut 250 µg at the M12 DBPCFC1 Global score and score of organ systems most likely to indicate a life-threatening response Global Severity Score Severe Moderate None or mild DBPCFC at b
Slide 35: Efficacy and safety in patients with concomitant allergic diseases at baseline
EFFICACY AND SAFETY OF VIASKIN™ PEANUT IN PATIENTS WITH CONCOMITANT ALLERGIC DISEASES AT BASELINE Concomitant Atopic Dermatitis1 Concomitant Asthma2 Concomitant Food Allergies3 at Baseline at Baseline at Baseline Efficacy and safety results similar irrespective of Efficacy and safety results sim
DBV Technologies — Investor Presentation (September 2021) on 6ix